GSK: GSK's Blujepa receives US FDA nod to treat uncomplicated urinary tract infections in female and paediatric patients 12 years of age and older

GSK plc, announced that the US FDA has approved Blujepa (gepotidacin) for the treatment of female adults (=40 kg) and paediatric patients (=12 years, =40 kg) with uncomplicated urinary tract infections (uUTIs) caused